BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 29407620)

  • 1. Point of Care Testing (POCT) to assess drug concentration in patients treated with non-vitamin K antagonist oral anticoagulants (NOACs).
    Padayattil Jose S; Banzato A; Carraro P; Haleh A; Rossi K; Nante G; Denas G; Zoppellaro G; Pengo V
    Thromb Res; 2018 Mar; 163():100-104. PubMed ID: 29407620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants.
    Ebner M; Birschmann I; Peter A; Spencer C; Härtig F; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
    Crit Care; 2017 Feb; 21(1):32. PubMed ID: 28196509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Point-of-Care Testing of Coagulation in Patients Treated With Non-Vitamin K Antagonist Oral Anticoagulants.
    Ebner M; Peter A; Spencer C; Härtig F; Birschmann I; Kuhn J; Wolf M; Winter N; Russo F; Zuern CS; Blumenstock G; Ziemann U; Poli S
    Stroke; 2015 Oct; 46(10):2741-7. PubMed ID: 26272385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study.
    Harenberg J; Du S; Wehling M; Zolfaghari S; Weiss C; Krämer R; Walenga J
    Clin Chem Lab Med; 2016 Feb; 54(2):275-83. PubMed ID: 26167981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant.
    Mani H; Herth N; Kasper A; Wendt T; Schuettfort G; Weil Y; Pfeilschifter W; Linnemann B; Herrmann E; Lindhoff-Last E
    Ther Drug Monit; 2014 Oct; 36(5):624-31. PubMed ID: 24577124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lupus-anticoagulant testing at NOAC trough levels.
    Ratzinger F; Lang M; Belik S; Jilma-Stohlawetz P; Schmetterer KG; Haslacher H; Perkmann T; Quehenberger P
    Thromb Haemost; 2016 Aug; 116(2):235-40. PubMed ID: 27075441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the Russell Viper Venom time test provide a rapid estimation of the intensity of oral anticoagulation? A cohort study.
    Douxfils J; Chatelain B; Hjemdahl P; Devalet B; Sennesael AL; Wallemacq P; Rönquist-Nii Y; Pohanka A; Dogné JM; Mullier F
    Thromb Res; 2015 May; 135(5):852-60. PubMed ID: 25743887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
    Prescrire Int; 2013 Jun; 22(139):155-9. PubMed ID: 23866358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel prothrombin time method to measure all non-vitamin K-dependent oral anticoagulants (NOACs).
    Lindahl TL; Arbring K; Wallstedt M; Rånby M
    Ups J Med Sci; 2017 Aug; 122(3):171-176. PubMed ID: 28891412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life.
    Giustozzi M; Vedovati MC; Verdecchia P; Pierpaoli L; Verso M; Conti S; Cianella F; Marchesini E; Filippucci E; Agnelli G; Becattini C
    Eur J Intern Med; 2016 Sep; 33():42-6. PubMed ID: 27394924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergency Coagulation Assessment During Treatment With Direct Oral Anticoagulants: Limitations and Solutions.
    Ebner M; Birschmann I; Peter A; Härtig F; Spencer C; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
    Stroke; 2017 Sep; 48(9):2457-2463. PubMed ID: 28775134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microfluidic coagulation assay for monitoring anticoagulant therapy in acute stroke patients.
    Bluecher A; Meyer Dos Santos S; Ferreirós N; Labocha S; Meyer Dos Santos IM; Picard-Willems B; Harder S; Singer OC
    Thromb Haemost; 2017 Feb; 117(3):519-528. PubMed ID: 28124061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 15. The non-vitamin K antagonist oral anticoagulants and heparin-induced prolongation of the activated coagulation time.
    Negro F; Caravelli P; Morganti R; Casini M; Ruocco L; Tripodi A; De Caterina R
    Vascul Pharmacol; 2022 Jun; 144():106994. PubMed ID: 35436607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples.
    Bonar R; Favaloro EJ; Mohammed S; Ahuja M; Pasalic L; Sioufi J; Marsden K
    Pathology; 2016 Jan; 48(1):60-71. PubMed ID: 27020211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of rivaroxaban on point-of-care assays.
    Fontana P; Alberio L; Angelillo-Scherrer A; Asmis LM; Korte W; Mendez A; Schmid P; Stricker H; Studt JD; Tsakiris DA; Wuillemin WA; Nagler M
    Thromb Res; 2017 May; 153():65-70. PubMed ID: 28343143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants including edoxaban.
    Härtig F; Birschmann I; Peter A; Hörber S; Ebner M; Sonnleitner M; Spencer C; Bombach P; Stefanou MI; Tünnerhoff J; Mengel A; Kuhn J; Ziemann U; Poli S
    Neurol Res Pract; 2021 Mar; 3(1):9. PubMed ID: 33641678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
    Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
    Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
    Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S
    Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.